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Preface
The Nordic Council of Ministers is an intergovernmental collaborative body for
the five countries, Denmark, Finland, Iceland, Norway, and Sweden. One of the
committees, the Nordic Senior Executive Committee for Occupational Environ-
mental Matters, initiated a project in order to produce criteria documents to be
used by the regulatory authorities in the Nordic countries as a scientific basis for
the setting of national occupational exposure limits.
The management of the project is given to an expert group. At present the
Nordic Expert Group (NEG) consists of the following members:
Gunnar Johanson, chairman Karolinska Institutet and National Institute for
Working Life, Sweden
Vidir Kristjansson Administration of Occupational Safety and Health,
Iceland
Kai Savolainen Finnish Institute of Occupational Health, Finland
Vidar Skaug National Institute of Occupational Health, Norway
Karin Sørig Hougaard National Institute of Occupational Health, Denmark
For each document an author is appointed by NEG and the national member acts
as a referent. The author searches for literature in different data bases such as
HSELINE, Medline and NIOSHTIC. Information from other sources such as
WHO, NIOSH and the Dutch Expert Committee on Occupational Standards
(DECOS) is also used as are handbooks such as Patty’s Industrial Hygiene and
Toxicology. Evaluation is made of all relevant scientific original literature found.
In exceptional cases information from documents difficult to access is used.
Whereas NEG adopts the document by consensus procedures, thereby granting
the quality and conclusions, the author is responsible for the factual content of the
document.
The document aims at establishing dose-response/dose-effect relationships and
defining a critical effect based only on the scientific literature. The task is not to
give a proposal for a numerical occupational exposure limit value.
The evaluation of the literature and the drafting of this document on ammonia
was made by Dr Jyrki Liesivuori, University of Kuopio, and Finnish Institute
of Occupational Health, Finland. The final version was accepted by NEG
September 9, 2005. Editorial work and technical editing was performed by NEGs
scientific secretaries, Anna-Karin Alexandrie and Jill Järnberg, at the National
Institute for Working Life in Sweden.
All criteria documents produced by NEG may be downloaded from
www.nordicexpertgroup.org.
We acknowledge the Nordic Council of Ministers for its financial support of
this project.
Anna-Karin Alexandrie, Jill Järnberg Gunnar Johanson
Scientific Secretaries Chairman
Abbreviations and acronyms
ACGIH American Conference of Governmental Industrial Hygienists
ATP adenosine triphosphate
CA chromosomal aberration
CI confidence interval
DEPC diethyl pyrocarbonate
EPA United States Environmental Protection Agency
FEV1 forced expiratory volume in one second
FVC forced vital capacity
FIV forced inspiratory volume
IPCS International Programme on Chemical Safety
LC50 lethal concentration for 50% of the exposed animals at single exposure
LD50 lethal dose for 50% of the exposed animals at single administration
LOAEL lowest observed adverse effect level
MNNG N-methyl-N’-nitro-N-nitrosoguanidine
MRL minimal risk level
NIOSH United States National Institute of Occupational Safety and Health
NMDA N-methyl-D-aspartate
NOAEL no observed adverse effect level
OSHA Occupational Safety and Health Association
PEFR peak expiratory flow rate
RADS reactive airways dysfunction syndrome
RD50 concentration, which produce a 50% decrease in respiratory rate
SCE sister chromatid exchange
SPIN Substances in Preparation in Nordic Countries
STEL short-term exposure limit
VC vital capacity
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11. Introduction
Ammonia (NH3) is a colourless gas with a distinctly pungent odour at normal
atmospheric temperatures and pressures. Ammonia dissolves readily in water and
a pH dependent equilibrium is established between NH3, and ammonium (NH4+)
and hydroxide (OH-) ions. The ionised form predominates in water solutions and
at physiological pH. NH3 diffuses more easily than NH4+ and can readily pass
across membranes. Unless otherwise stated, the term ammonia in this document
refers to the sum of NH3
 
and NH4+.
Ammonia is an endogenous compound produced in different metabolic
reactions in the human body. The steady-state level of ammonia in the liver is
about 0.7 mM and in blood plasma about ten times lower (151).
The principal source of atmospheric ammonia is animal husbandry and the
remainder is largely released from fertilisers (147). A small fraction originates
from crops as leaf emissions. Ammonia is one of the most extensively used
industrial chemicals. Occupational exposures may occur in ammonia plants,
fishing industries, fertiliser manufacturing and animal production (poultry, pigs
and fur animals).
This document is limited to anhydrous ammonia and aqueous ammonia
solutions although ammonia may also react with other substances to form
ammonium compounds including salts such as ammonium chloride, ammonium
nitrate, and ammonium sulphate. A criteria document on ammonia was written
for the Nordic Expert Group for Criteria Documentation of Health Risks from
Chemicals (NEG) in 1986 (110).
2. Substance identification
CAS No.: 7664-41-7
EINECS No.: 2316353
IUPAC name: ammonia
Molecular formula: NH3
Molecular weight: 17.03
Structural formula:
N
HH
H
23. Physical and chemical properties (12, 62, 87)
Boiling point at 101.3 kPa: -33.4°C
Melting point at 101.3 kPa: -77.7°C
Vapour pressure at 20°C: 857 kPa
Density, gas at 101.3 kPa and 0°C: 0.7714 g/l
Vapour density (air = 1): 0.6
Density, liquid at 101.3 kPa and -33.4°C: 0.6818 g/l
Viscosity at -33°C: 0.254 centipoise
Viscosity at 20°C: 0.00982 centipoise
Flammability limits:  Lower explosive limit 16% vol
                                   Upper explosive limit 27% vol
Autoignition temperature: 651°C
Critical temperature: 132.45°C
Critical pressure at 25°C: 11379 kPa
Solubility in water at 101 kPa and:  0°C 895 g/l
                                                       20°C 529 g/l
                                                       40°C 316 g/l
                                                       60°C 168 g/l
Partition coefficients:  Log Kow (octanol/water) 0.23
                                    Log Koc (octanol/carbon) 1.155
Odour threshold: 5-6 ppm
Conversion factors at 25°C: 1 mg/m3 = 1.4 ppm
1 ppm = 0.7 mg/m3
Ammonia (NH3) is a colourless gas with a distinctly pungent odour under normal
conditions. It can be compressed and become a liquid under high pressure. NH3
easily dissolves in water. In aqueous solution, NH3 acts as a base, acquiring
hydrogen ions from water to yield ammonium (NH4+) and hydroxide (OH-) ions.
The equilibrium between NH3 and NH4+ is pH-dependent. The pKa for ammonia
depends on the temperature, being 9.1-9.2 at 37°C. Thus, under normal physio-
logical conditions, more that 98% of ammonia is present as NH4+ (56).
The given odour threshold is obtained from Devos et al, who based their
estimates on 11 studies (45). In a more recent study by Sundblad et al the subjects
detected the smell of ammonia at 5 ppm, the lowest concentration tested (173).
34. Occurrence, production and use
Ammonia is one of the principal compounds in the natural cycle of nitrogen
in the environment. It is present in air both as a gas, as ammonium salts in
aerosols, and as ammonium ions dissolved in droplets after reactions with acidic
air components, e.g. sulphur dioxide. Ammonia concentrations are higher over
continents than over oceans and also higher in urban than in rural areas. Reported
levels vary from 1 to 16 μg/m3 (1.4-23 ppb). The concentrations tend to be higher
in summer than in winter (11). Ammonia can be detected in indoor air, as emis-
sions from textiles and some floor and wall materials. Ammonia is present in
several agricultural activities and is formed in animal facilities mainly from
manure (53).
Ammonia is one of the most commonly produced inorganic compounds in the
chemical industry. World industrial ammonia production grew from 119 million
tons in 1980 to a peak of 141 million tons in 1989. Since then, the production has
remained relatively stable with increases only in Asia for fertiliser production.
Use of ammonia in other industrial processes does not seem to increase further
(86). For industrial use, ammonia is synthesised from nitrogen and hydrogen with
catalysts by the Haber-Bosch method. Eighty-five per cent of the total production
is further processed for fertiliser production. Anhydrous ammonia is widely used
as an inexpensive fertiliser (169). Ammonia was used as a coolant for decades,
but other compounds have now replaced it as freezing agent in industrial refri-
gerators. However, ammonia is still used in a wide range of commercial and
consumer products, including caustic cleaners, chemical synthesis, explosives,
plastics, and dyes.
Ammonia gas is commercially available in a number of grades depending on its
intended use with a minimum purity of 99.5%. Ammonia is shipped and stored as
a liquefied gas under high pressure. It is also available in water solution with the
most common commercial formulation containing 28-30% ammonia. Solutions of
greater than 25-30% readily give off ammonia gas at normal temperatures. House-
hold products typically contain lower levels of ammonia ranging between 5 and
10% (32).
The use of ammonia in the Nordic countries as reported in the chemical product
data base “Substances in Preparation in Nordic Countries” (SPIN), both as totals
and for different purposes, is shown in Table 1.
Ammonia is one of the by-products of protein metabolism, and it is normally
found in the blood of healthy human subjects at levels below 0.05 mM (41) and
in saliva at concentrations of 2.5 mM (84). The steady-state level of ammonia
in liver has been reported to be 0.7 mM (151). The concentration of urinary
ammonia ranges from 8 to 80 mM in healthy people or approximately 1 000-
fold higher than in serum ammonia (95). Muscular activity results in ammonia
release and blood and urinary levels may increase after exercise (135). Estimated
ammonia production from various substrates in the human intestines ranges from
10 mg/day in the duodenum to 3 080 mg/day in the colon and faecal contents.
4Table 1. Annual ammonia consumption in the Nordic countries as reported for 2002 in
the chemical product data base “Substances in Preparation in Nordic Countries” (SPIN)
(170).
Country Use category Tonnes
Finland Total 374 120
Sweden Total 209 996
Raw materials 114 889
pH-regulating agents        862
Fertilisers        381
Galvano-technical agents        344
Metal-staining agents        162
Norway Total 160 141
Raw materials and intermediate products 160 105
Cleaning and washing agents          29
Denmark Total   11 311
Nearly all the ammonia produced in the intestines is absorbed (172). Some
drugs and chemicals may affect liver and kidney functions and cause an increase
of serum ammonia levels. This is seen, for example, after valproate therapy in
patients with epilepsy (186) or after exposure to ethylene glycol ethers (103).
5. Measurements and analysis of workplace exposure
The most widely used technique for the sampling of ammonia in workshop air is
an impinger flask containing diluted sulphuric acid. Samples are then analysed
with a gas selective electrode (137). Another possibility is Nesslerisation in
which ammonia reacts in dilute sulphuric or boric acid with an alkaline mercuric
and potassium iodide solution to form a brown complex. The concentration is
obtained by spectrophotometry, with the absorbance value at 440 nm being
compared with a standard (6). A more sophisticated way to analyse ammonia is
by ion chromatography (73). Also direct-reading instruments based on infrared
spectroscopy have been shown suitable for measuring ammonia in air. Detector
tubes specific for ammonia are available for measurements in the range 1-17 000
ppm (119).
Ammonia may be present in air in both the vapour and particulate phase
as ammonia gas and as ammonium salts. In order to avoid interactions from
ammonium salts and to separate the particulate phase, the use of filter packs or
sampling tubes coated with a selective adsorbent is recommended (98). The
gaseous ammonia is trapped by acids that act as adsorbents on the coated filter
or sampling tube. Examples of methods used for determination of ammonia in
air are given in Table 2. The recovery is over 95% for most methods.
5Table 2. Sampling and analytical methods for determining ammonia in air. Adapted
from ATSDR (12).
Preparation method Analytical method Detection limit
(μg NH3/sample)
Ref.
Passive collection using H2SO4 in
liquid sorbent badge
NIOSH method 6701,
ion chromatography,
conductivity detection
1 (138)
Air samples (stack emissions) collected
through an in-stack filter and then
bubbled through H2SO4
EPA method 30,
ion chromatography
1 (52)
Prefilter may be used. Ammonia
trapped on H2SO4 - treated silica gel
NIOSH method 6015, colorimetric
determination of indophenol by
visible light spectrophotometry
0.5 (139)
Prefilter may be used. Ammonia
trapped on H2SO4 - treated silica gel
NIOSH method 6016,
ion chromatography
2 (140)
Chromatomembrane cells pre-extract
and preconcentrate sample
Ion chromatography with
conductivity detection
6 (54)
Collection in H2SO4 - coated activated
carbon beads in sampling tube
OSHA method ID-188,
ion chromatography
2 (19)
Known volume of air drawn through
prefilter and H2SO4 - treated silica gel
NIOSH method S347,
ammonia-specific electrode
   Not
reported
(171)
In biological samples like blood, plasma, and serum, ammonia is present mainly
as ammonium ion. Therefore, the analysis starts with liberation of ammonia by
distillation, aeration, ion-exchange chromatography, microdiffusion, or depro-
teinisation. Ammonia in urine has been measured by Nesslerisation, enzymatic
assays, and chromatographic methods (83). Direct-reading blood ammonia
checker based on gas specific potentiometry has been used to assay ammonia in
biological samples (119, 155). Some examples of methods used for ammonia
determination in biological samples are given in Table 3. Sample detection limits
were not reported in any source.
Table 3. Analytical methods for determining ammonia in biological samples. Adapted
from ATSDR (12).
Sample matrix Analytical method Reference
Urine Colorimetric (Berthelot reaction) (176)
Urine Indophenol reaction (83)
Urine Glutamate dehydrogenase based auto-analyser method (95)
Saliva Membrane based ammonia-selective electrode (83)
Serum, plasma, whole blood Colorimetric assay based on indophenol production (83)
Serum, plasma, whole blood Titration (83)
Serum, plasma, whole blood Membrane based ammonia-selective electrode (130)
66. Occupational exposure data
Occupational exposure to ammonia occurs primarily via inhalation. Dermal
exposure may also occur due to splashes and spills during handling of aqueous
solutions. Only in accidental situations may ammonia be swallowed. Ammonia
concentrations have been measured at different work-sites from agriculture
(animal production) to process work in factories as well as in blue-line printing
shops (Table 4).
Table 4. Occupational exposure levels of ammonia at different work-sites. Most
measurements were personal samples.
Work-site Country Exposure levels Reference
   mg/m3          ppm
Hairdressing salon Finland 1.4 – 3.5 2.0 – 5.0 (109)
The Netherlands 0.02 – 0.43 0.03 – 0.62 (184)
Blue-line printing shop USA 0.7 – 28 1.0 – 40 (181)
Swine confinement buildings USA 2.3 – 17.5 3.3 – 25.0 (47)
United Kingdom 1.0 – 9.2 1.5 – 13.2 (39)
Finland 0.7 – 23.8 1.0 – 34.0 (116)
Taiwan < 3.5 < 5.0 (31)
The Netherlands 0.1 – 17.3 0.2 – 24.7 (74)
The Netherlands 0.2 – 2.9 0.3 – 4.2 (152)
Sodium carbonate production USA 6.4 ± 1.0a 9.2 ± 1.4a (81)
Animal facility (mouse rooms) USA 0.07 – 1.0 0.1 – 1.4 (90)
Poultry house Iran 23.2 ± 3.6b 33.2 ± 5.2b (65)
 Cage-laying house Finland 6.2 – 55.2 8.8 – 78.9 (119)
 Cage-laying house Finland 2.1 – 27.9 3.0 – 39.8 (121)
 Floor-laying house Finland 20.1 – 40.3 28.7 – 57.6 (121)
 Barn systems United Kingdom 7.7 11 (195)
 Cage systems United Kingdom 4.9 7 (195)
Agricultural slurry stores United Kingdom 0 – 2.7 0 – 3.8 (71)
Municipal sewage plants Finland 0.007 – 3.48 0.01 – 4.97 (92)
Indoor air (during painting) Sweden 0.3 – 2.7 0.4 – 3.9 (141)
Finland 0.0007 – 0.052 0.001 – 0.075 (180)
Effluent treatment plant of pulp mill USA 0.07 – 20.3 1.0 – 29.0 (68)
a mean ± standard error of mean.
b mean ± standard deviation.
7The International Programme on Chemical Safety (IPCS) presents the highest
occupational ammonia exposures at mildew-proofing (122.5 ppm), electroplating
(53.9 ppm), galvanising (9.8-86.2 ppm), and chemical mixing (58.8-431.2 ppm)
(87). In agricultural settings, the ammonia concentrations seem to be higher in
poultry houses (mean 1.6-29.6 ppm, range 1.6-72.9) than in cow houses (mean
0.3-7.7 ppm, range 0.1-29.6), and possibly also in swine houses (4.3-20.8 ppm,
range 0.23-59.8) (145).
Ammonia seems to be an indoor air pollutant, although it has not been reliably
confirmed whether the measured compound is in fact ammonia or amine degrada-
tion products from protein-containing gluing material. Ammonia concentrations
in indoor air samples vary from 10 to 110 μg/m3 (14-154 ppb) as measured in
Finnish residencies (28, 180, 187). In Croatia, in the vicinity of a fertiliser plant,
indoor air ammonia concentrations ranged from 32 to 352 μg/m3 (45-493 ppb)
while ambient air ammonia concentrations were of the same order of magnitude,
from 4 to 420 μg/m3 (6-590 ppb) (66).
Concentrations may be unpredictably high under accidental circumstances
where ammonia gas is released into air (131, 174). Because of the sudden nature
of accidents only retrospective estimates of exposure levels are available in the
literature. There is one estimate of an exposure level, a report of a fatality at a
concentration of approximately 10 000 ppm (134). In this case, a victim was
filling a tank wagon with a 25% ammonia solution. Later, it was estimated that
the ammonia concentrations may have reached 330 000 ppm, at least sporadically
(131).
7. Toxicokinetics
7.1 Uptake
Absorption of ammonia is strongly pH dependent. At higher pH, ammonia is
present as a gaseous, relatively lipophilic molecule (NH3), which readily diffuses
through cellular and intracellular membranes. At lower pH, ammonia exists as an
ion (NH4+), with ionic radius and properties similar to that of the potassium ion
(K+). The NH4+ ion, like K+, can only be transported across membranes by carrier-
mediated processes (38). The ionised form predominates (more than 98%) at
physiological pH.
The primary site of absorption is the upper respiratory tract. However, in case
of aerosols in the air and high humidity, ammonia can adsorb onto the aerosols
and be carried deeper into the lungs. Ammonia is probably absorbed percutane-
ously, if high concentrations are spilt on intact skin and have caused skin injury
(62). Absorption through the eye has been reported. Ammonia diffused within
seconds into cornea, lens, drainage system, and retina. However, the amounts
absorbed were not quantified, and absorption into systemic circulation was not
investigated (16, 89 cited in 12).
8The knowledge of the toxicokinetics of ammonia is limited and information
is primarily available from older human experimental studies. When seven
volunteers were exposed to an ammonia concentration of 350 mg/m3 (500 ppm)
for 30 minutes the retention was around 75%. The ammonia retention decreased
progressively with time, reaching 23% at steady-state. No effect on blood-nitrogen
was seen (166). In a study by Landahl and Herman two male volunteers were
exposed to ammonia concentrations ranging from 40 to 350 mg/m3 (57-500 ppm)
for a maximum of 2 minutes. About 92% retention was reported and the exposure
level did not affect the retention (104). It is estimated in the IPCS document that
exposure to 25 ppm ammonia would raise the blood ammonia concentration by
only 10% over fasting levels assuming 30% retention (87). This slight increase is
evaluated to be well within the normal human capacity to handle ammonia and is
unlikely to cause any harm (174).
In healthy subjects, absorbed ammonia is rapidly catabolised by the liver, mainly
to urea. Only relatively small amounts reach the systemic circulation from the
gastrointestinal tract as a consequence of this first pass effect (172).
Ammonia absorbed from the intestinal tract arises primarily from bacterial
degradation of amino and nucleic acids in ingested food, endogenous epithelial
debris, and mucosal cell luminal secretions, or from the hydrolysis of urea
diffusing from the systemic circulation into the intestinal tract. Ammonia uptake
from the human colon, the major site of ammonia production, increases with
increasing pH of the luminal contents. An increase in pH raised the proportion
of non-ionised ammonia, showing that most of the ammonia transport relies on
passive diffusion. However, ammonia transport, although greatly diminished, still
occurred when the luminal pH was reduced to 5, suggesting an active transport
mechanism for the ammonium ion (29).
In a study of cerebral uptake of labelled ammonia in Rhesus monkeys it was
found that after passage of the bolus, a fraction of 40% remained in the brain
(148). The brain content of tracer remained almost stable with a half-time of 45
minutes. Similar observations were reported in man albeit with a half-time of
2.3 hours (149).
In rats exposed to ammonia via inhalation 6 hours/day for 5 days, venous
blood ammonia increased linearly from a baseline value of 35 ± 18 mM
(mean ± standard deviation) to 44 ± 18 mM at 25 ppm and to 105 ± 14 mM at
300 ppm. However, in rats exposed to the same concentrations for 10 or 15 days
the relationship between dose and blood ammonia level was lost, suggesting
metabolic adaptation (120). Rats were continuously exposed to ammonia
concentrations of 15, 32, 310, or 1 157 ppm for 24 hours and blood ammonia
concentration was measured 0, 8, 12 and 24 hours after exposure began. The
blood ammonia level increased significantly in a linear fashion with increasing
exposure after 8 hours of exposure. The levels declined over time, indicating an
increased ammonia metabolism (160).
97.2 Distribution
The distribution of ammonia between body compartments is strongly influenced
by pH. The non-ionised ammonia is freely diffusible, whereas the ammonium
ion is less diffusible and relatively confined in compartments (62). Ammonium
ions compete with potassium ions for inward transport over the cytoplasmic
membrane, via potassium transport proteins like the Na+/K+-ATPase and the
Na+K+2Cl--cotransporter (124).
Ammonia enters the brain from blood by diffusion rather than via a saturable
transport system. It has been estimated that up to 25% of ammonia may enter
the brain as ammonium ion at physiological pH values. The blood transit time
through brain is in the order of seconds, and the NH4+ to NH3 conversion rate is
too rapid to limit the rate at which ammonia enters the brain. The lower permea-
bility of the blood-brain barrier to NH4+ implies that transfer of ammonia is
dependent upon arterial blood pH and systemic alkalosis exacerbates ammonia
toxicity (146, 192). This is consistent with a higher rate of diffusion of NH3 into
brain at higher blood pH values (56).
Since diffusion of ammonia into the brain is pH dependent, the pH gradient
between blood and brain may affect brain ammonia concentrations (56).
Assuming a blood pH of 7.4 and a brain intracellular pH of 7.1 under normal
physiological conditions, the Hendersson-Hasselbach equation predicts a ratio of
brain to blood ammonia concentrations of 2 (38). Experimental ratios range from
1.5 to 3.0. In hyperammonaemia, the ratio may rise to even 8 (27, 56). In chronic
liver failure, prior to the onset of encephalopathy, blood ammonia concentrations
are increased by three-fold in both experimental animals and humans (115) and
brain concentrations are in the 0.3-0.5 mM range (64). The steady-state level of
ammonia in the liver of healthy subjects is about 0.7 mM and about ten times
lower in blood plasma (151).
7.3 Endogenous ammonia
In humans and several other species ammonia plays a central role in nitrogen
metabolism (Figure 1).
Ammonia is both a product of protein and nucleic acid catabolism, and a pre-
cursor for non-essential amino acids and certain other nitrogenous compounds.
The liver is the major site of ammonia metabolism.
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Figure 1. Exogenous and endogenous sources of ammonia in vertebrates. Adapted from
Seiler (161).
The major features of nitrogen in the body include:
– release of nitrogen from amino acids, nucleic acids, and amines,
– deamination of glutamate through the action of glutamate dehydrogenase,
– conversion of ammonia to urea by the Krebs-Henseleit (urea) cycle (Figure 2),
– conversion of urea to ammonia in the gastrointestinal tract by the action of
bacterial urease, and
– synthesis of glutamine serving as a short-term storage and transport form of
ammonia in the glutamine cycle (Figure 3).
The Krebs-Henseleit (urea) cycle is tightly controlled to dispose approximately
90% of the surplus nitrogen (Figure 2).
Glutamine is quantitatively the second major product of hepatic ammonia
metabolism and serves an additional important function in the storage and
transport of ammonia (Figure 3). The synthesis of glutamine also provides a
detoxification mechanism for ammonia in the brain through a single enzymatic
step, i.e. via the glutamine synthetase catalysed reaction localised in astrocytes
(38). The two nitrogens of glutamine are the major ammonia precursors for
ammoniagenesis in the kidney tubular cells of most vertebrates. The ammonia
formed in this way enters urine and forms ammonium ions there (151).
Deamination of
aminopurines and
aminopyrimidines
Oxidative deamination
of primary amines
Degradation of amino acids
(glycine, glutamine, etc.)
Degradation of
hexosamines
Hydrolysis of protein
amido groups
Bacterial infections of
urinary tract (ureas)
Gastrointestinal tract
(bacteria, proteins, etc.)
EXOGENOUS SOURCES
ENDOGENOUS SOURCES
  AMMONIA
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Figure 2. The Krebs-Henseleit (urea) cycle (108). AMP: adenosine monophophate, ADP:
adenosine diphoshate, ATP: adenosine triphosphate, Pi: inorganic phosphate (HPO42-),
and PPi: pyrophosphate (P2O74-).
Figure 3. Glutamine cycle. Modified from Brunner and Thaler (25).
Glutamate
Glutamate
NH4+
NH4+
Glutamine
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Glutaminase
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Table 5. Arterial blood ammonia concentrations in healthy volunteers and in patients
with liver disease (144).
Subjects Arterial ammonia
concentration (mM)
Reference
Healthy volunteers 0.045 (33)
Patients with chronic liver failure and proven cirrhosis 0.060 (33)
Cirrhotic patients with transjugular intrahepatic portosystemic
stent shunta
0.080 (156)
Patients with acute-on-chronic liver disease 0.090-0.120 (33)
Patients with acute liver failure 0.150-0.180 (33)
Patients with end stage acute liver failure 0.340 (88)
aA non-surgical technique for treatment of refractory ascites associated with cirrhosis of the liver.
Mutch and Bannister reviewed the relationship between muscle activity and
ammonia production. The immediate source of ammonia from muscle appears
to be a result of the deamination of adenosine monophosphate, which is more
apparent in fast twitch fibres than in slow twitch fibres. An increase of blood
ammonia levels both in rats after swimming and in humans after manual work,
maximal cycle ergometry, and treadmill exercise is observed (135). In a more
recent study, heat stress and exercise increased plasma ammonia from preexercise
level to 0.06-0.07 mM at the end of submaximal runs, and further to 0.11 mM at
the end of performance runs in hot conditions (123). The accumulation of plasma
ammonia following sprint exercise is about 35% lower in women than in men
(55).
Arterial blood ammonia concentrations in healthy volunteers and in patients
with liver disease are shown in Table 5.
A variety of xenobiotics (methanol, formic acid, cyanide, 2-ethyl-hexanoic
acid, valproate, and acetaminophen) may impair liver function resulting in
increased blood and urine ammonia level (72, 112, 113, 122, 153). Elevated
ammonia levels may also be a result from xenobiotics affecting the kidney
function. This is seen, for example, after valproate therapy in patients with
epilepsy (186) or after exposure to ethylene glycol ethers (103).
Congenital deficiency of enzymes in the urea cycle, such as carbamoyl phos-
phate synthetase I and, to a lesser extent, ornithine transcarbamylase, as well as
several other metabolic disorders like arginosuccinic aciduria may lead to
hyperammonaemia and various abnormal urinary constituents (10, 82, 162).
7.4 Biotransformation
Exogenous ammonia, administered intravenously as an ammonium compound,
is metabolised to glutamine as the major early product (51). Following admini-
stration of 13N-ammonia to rats (via either the carotid artery or cerebrospinal
fluid), most of the metabolised label was recovered in glutamine (amide) and
minor fractions in glutamate and aspartate. Although ammonia in blood and
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cerebrospinal fluid are converted largely to glutamine, it is not possible to predict
with certainty the metabolic fate of the bulk of endogenously produced ammonia
(36). The ammonia fixed in glutamine may eventually end up in amino acids,
purines, pyrimidines, or other nitrogen-containing compounds.
Ingested ammonium chloride and endogenous intestinal ammonia enters
the liver via the portal vein and is converted to urea (59, 67, 150). In humans,
absorbed ammonia (both exogenous and endogenous) is converted to the
ammonium ion as hydroxide and as salts, especially as carbonates. The
ammonium salts are then rapidly converted to urea. Protein deamination in the
body yields ammonium ions, which are rapidly converted into urea in the liver
and excreted by the kidney or used for synthesis of amino acids. Ammonium
ions are produced in the kidney in order to maintain electrolyte balance (62).
The hepatic first-pass metabolism of ammonia has been quantified with
positron emission tomography (96). The estimate of the hepatic extraction of
ammonia in the intact pig was around 0.7. Assuming that 75% of the liver blood
flow passes through the portal vein and 25% through the hepatic artery, and using
the published values of the blood concentrations in arteries, the hepatic vein, and
the portal vein, recalculated values of the hepatic extraction fraction of ammonia
were 0.60 in liver patients undergoing surgery, 0.85 in rats and 0.95 in dogs (30,
37, 127). Around one-half of the ammonia is converted to urea in the periportal
zone and around one-half to glutamine in the perivenous zone (Figure 4). Urea
synthesis accounts for two-thirds of the ammonia utilisation by isolated rat
hepatocytes (96).
The synthesis of urea (mechanism for conjugating ammonia into non-toxic
compounds for excretion in mammals) requires the concerted action of several
enzymes of the urea cycle (Figure 2). One of these, the cytosolic glutamine
synthetase, is present in several organs including the brain and the liver.
Glutamine synthesis is the most important alternative pathway for ammonia
detoxification. Glutamine synthetase catalyses the synthesis of glutamine from
equimolar amounts of glutamate and ammonia (Figure 3) (197). Glutamine is the
most abundant free amino acid in the body, with the highest plasma concentration
(102). Other organs can take up glutamine where it is split by the intramitochon-
drial phosphate-dependent enzyme glutaminase into glutamate and ammonia. The
glutaminase present in the liver is activated by ammonia, in contrast to other types
of glutaminases, which are inhibited by ammonia (40). A schematic representation
of ammonia and glutamine trafficking between different organs is given in
Figure 4.
Glutamate can be used in transamination reactions, yielding predominantly
alanine. Alanine can be released into the bloodstream, and transported to the liver,
where the carbon skeleton can be used for gluconeogenesis (144).
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Figure 4. Schematic representation of the predominating ammonia and glutamine
turnover between body compartments. Modified from Olde Damink et al (144).
7.5 Excretion
In humans, ammonia is primarily excreted via the kidneys. In addition, a
significant amount is excreted via the sweat glands (62). Ammonia is mainly
excreted as urea by mammals. However, ammonia may also be directly excreted
in urine. Glutaminase catalyses the release of ammonia in the kidney tubular
epithelium. In acidosis, the renal concentration of glutaminase increases over
several days, in parallel with increased excretion of ammonium ions. Two-thirds
of the urinary ammonia is excreted via this pathway and approximately one-third
is consumed by protein metabolism and ammonia clearance from the plasma
by the kidney (91). Renal ammoniagenesis in the proximal tubule is highly
increased by chronic metabolic acidosis where glutamine is the major substrate.
The mitochondrial glutaminase produces ammonium and glutamate ions.
Ammonium is secreted as ammonia and hydrogen ion by separate mechanisms
producing ammonium cations in the lumen, and thereby regulating the acid-base
balance of the organism (164).
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Ammonia may also be excreted through expired air. Reported levels of ammonia
in expired air are 0.1-2.2 mg/m3 (0.15-3.1 ppm) (85) and 0.2-1.2 mg/m3 (0.3-1.7
ppm) (105). These values, higher than those expected from equilibrium with
plasma- and lung-parenchyma- ammonia levels (0.03-0.05 mg/m3) (0.04-0.07
ppm), are most likely due to the synthesis of ammonia from salivary urea by the
oral microflora (62).
Less than 1% of the total ammonia produced in the human intestinal tract
(4 g/day) is excreted in the faeces (172).
8. Biological monitoring
Ammonia is endogenously produced and is present in all body fluids. The
generally accepted reference level used in clinical laboratories for blood ammonia
of healthy subjects is 0.05 mM although lower levels of 0.005-0.007 mM have
also been suggested (41). In unexposed healthy subjects the urinary ammonia
level is reported to be below 1.4 mol/mol creatinine corresponding to about 10
mM (112). In clinical chemistry, urinary ammonia levels from 8 to 80 mM are
regarded as normal values (95). The mean ammonia concentration in saliva of
healthy subjects is 2.5 mM (84).
Rats exposed to ammonia vapour showed dose-dependent blood ammonia
levels after 5 days of exposure (6 hours per day). However, blood ammonia
concentrations had returned to baseline levels after 10 and 15 days of continued
exposure (120). In rats continuously exposed to ammonia for 24 hours the level in
blood declined over time indicating increased ammonia metabolism during the
exposure (160).
There are no reports of increased urinary ammonia excretion after occupational
exposure. Inhalation by volunteers of 500 ppm ammonia for 30 minutes did not
have any effect on blood and urine nitrogen levels (166). It has been estimated
that exposure to 25 ppm ammonia increases the blood ammonia concentration by
only 10% over fasting levels, assuming 30% retention (87). However, ammonium
concentrations in blood and urine may be assayed for clinical changes caused by
ammonium salts and other chemicals affecting the urea cycle like acetaminophen,
valproate, 2-ethylhexanoic acid, and formic acid (72, 79, 101, 113).
Due to relatively high endogenous production and adaptive metabolism, bio-
monitoring of occupational exposure to ammonia seems of little value.
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9. Mechanisms of toxicity
Ammonia as a gas, in anhydrous form or in concentrated solutions, possesses
corrosive properties, and massive exposure leads to necrosis of skin and mucous
membranes. Ammonia may also cause sensory airway irritation as the trigeminal
nerve is affected (131, 174).
The topical damages caused by ammonia are mainly due to its alkaline proper-
ties. Because of the high water solubility ammonia dissolves in moisture on
the mucous membranes, skin, and eyes, forming ammonium hydroxide, which
cause a liquefaction necrosis of the tissues (89). Ammonium hydroxide increases
saponification of cell membrane lipids resulting in cell disruption and death.
Further, it breaks down cell structural proteins, extracts water from the cells, and
initiates an inflammatory response, which damages the adjoining tissues. This
reaction is exothermic contributing to tissue damage by cryogenic (thermal) injury
in addition to the alkali burns (7, 9).
The most serious effect of elevated endogenous ammonia is seen in the brain
as hepatic encephalopathy due to acute or chronic liver failure. Ammonia is
metabolised by glutamine synthase localised in astrocytes. Astrocytes are also
involved in the uptake of glutamate, an endogenous and most abundant cerebral
neurotransmitter that is the primary agonist for N-methyl-D-aspartate (NMDA)
receptors (142). Thus, the NMDA receptor is also a primary target of ammonia
toxicity. The ammonium ion is transported into the cell via the binding sites for
K+ because of similar ionic radius of hydrated ammonium and K+ (124).
Ammonium neurotoxicity is thus mediated through the activation of NMDA
receptors, increased activity of constitutive neuronal nitric oxide synthase, and
subsequently increased formation of nitric oxide that serves as a neurotransmitter
in a number of neuronal cells (56, 125). Nitric oxide in turn activates guanylate
cyclase leading to increased formation of cyclic guanosine monophosphate (77).
A key effect of ammonia at the cellular level is oxidative stress due to the
generation of reactive oxygen and nitrogen species subsequent to activation of
NMDA receptors. These events are associated with mitochondrial dysfunction
characterised by increased permeability of mitochondrial transition pore. The
opening of the transition pore is associated with cytochrome C release and
activation of a cascade of serinine-threonine proteases, also called caspases.
Simultaneous decrease of protein kinase C activity is associated with decreased
phosphorylation and activity, of Na+/K+-ATPase, depletion of ATP (99), and
increased levels of free intracellular calcium, toxic to neuronal cells (100). These
events are key-elements in the pathway leading to ammonia-induced programmed
cell death, apoptosis (143). Key-events of ammonia-induced effects on neuronal
cells are depicted in Figure 5.
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Ammonia exposure
↓
 Activation of N-methyl-D-aspartate receptors
↓
 Generation of reactive oxygen and nitrogen species
↓
 Oxidative stress
↓
 Mitochondrial transition pore permeability increases, mitochondrial dysfunction,
 universal disruption of cellular functions due to shortage of energy
↓
 Activation of caspase pathways
↓
 Programmed cell death
Figure 5. Schematic representation of mechanisms of ammonia-induced neurotoxicity.
10. Effects in animals and in vitro studies
10.1 Irritation and sensitisation
Male Swiss-Webster mice were exposed for 30 minutes by inhalation to con-
centrations of ammonia ranging from 100 to 800 ppm. The maximum depression
in respiratory rate at each exposure level occurred within the first 2 minutes with a
concentration-effect relationship. The calculated concentration associated with a
50% decrease in respiratory rate (RD50) was 303 ppm (15). In another study where
Swiss OF1 mice were exposed to ammonia the calculated RD50 value was 257
ppm. The minimal concentration at which nasal histopathological changes were
observed was 711 ppm after a 4-day exposure, 6 hours/day (201).
The National Research Council studied ocular toxicity of ammonia in rabbits
(136). Conjunctival oedema with ischaemia and segmentation of limbal vessels
were seen after 30 minutes exposure. By 24 hours, there was a reduction in
mucopolysaccharide contents of the corneal stroma, and extensive polymorpho-
nuclear infiltration and anterior lens opacities were apparent. In rabbits with
corneal burns, neovascularisation occurred after one week, but it was delayed in
animals with corneal limbal burns. Complications of severe burns included
symblepharon (adhesion of the conjunctival surface between the eyelid and the
eyeball), pannus (abnormal membrane-like vascularisation of the cornea),
pseudopterygia (a patch of thickened conjunctiva extending over a part of the
cornea), progressive or recurrent corneal ulcerations leading to perforations,
permanent corneal opacity, corneal staphyloma (a defect in the eye inside the
cornea), persistent iritis, phthisis bulbi, secondary glaucoma, and dry eye (136,
cited in 87).
No data on sensitisation of animals after ammonia exposure are available.
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10.2 Effects of single exposure
In an acute inhalation study on male ICR mice by Kapeghian et al, the lethal
concentration for 50% of the exposed animals (LC50) at a single 1-hour exposure
with a 14-days observation period was calculated to be 2 960 mg/m3 (4 230 ppm)
(93). Lungs of mice that died during the exposure (or during the 14 days observa-
tion period) were diffusely haemorrhagic. Histology revealed acute vascular
congestion and diffuse intra-alveolar haemorrhage. A mild to moderate degree of
chronic focal pneumonitis was also seen. There was evidence of swelling and
increased cytoplasmic granularity of hepatocytes and scattered foci of frank
cellular necrosis. The acute LC50 in male and female Wistar rats was 31 612
mg/m3 (40 300 ppm) for a 10-minutes exposure and 11 620 mg/m3 (16 600 ppm)
for a 60-minutes exposure (8). During the exposure, clinical signs of restlessness,
eye irritation, nasal discharge, mouth breathing, and laboured respiration were
seen. Gross necropsy revealed haemorrhagic lungs in animals that died during the
study as well as in survivors. In another study, the calculated 1-hour LC50 values
in rat and mouse of 5 137 and 3 386 mg/m3 (7 338 and 4 837 ppm), respectively
(118) were of the same order as those calculated by Kapeghian et al (93).
Additional reported LC50 values in animals exposed to ammonia are given in
Table 6. The cited studies on acute toxicity are somewhat old and were not carried
out according to present standards. Nevertheless, taken together they present a
consistent picture of short-term LC50 values of several thousand ppm.
White rats exposed to ammonia concentrations from 300 to 3 000 mg/m3 (431-
4 307 ppm) for 5-60 minutes expressed decreased static muscle tension, leuko-
cytosis, prolongation of latent reflex time, and increases in total protein, blood
sugar, oxygen consumption and residual nitrogen. No changes were observed in
rats exposed at 100 mg/m3 (143 ppm) for 5-60 minutes. A no observed adverse
effect level (NOAEL) of 100 mg/m3 (143 ppm) was concluded from this study
(154). Alpatov and Mikhailov regarded 85 mg/m3 (121 ppm) as a threshold level
for acute effects (depression followed by hyperactivity and convulsion) after 120
minutes exposure of albino rats (5, cited in 87).
Clinical and histological effects have also been seen in the lungs of other
animal species (cats, mice, and rabbits) following exposure to ammonia gas (46,
60, 167). Cats exposed to 1 000 ppm ammonia gas for 10 minutes and observed
for up to 35 days showed a biphasic course of respiratory pathology (46). Effects
seen at 24 hours after exposure included severe dyspnoea, anorexia, and dehydra-
tion, with rhonchi and course rales evident upon auscultation. Microscopy of
lung samples on day 1 showed necrotising bronchitis in the large conducting
airways, and necrosis and sloughing of the epithelium, and acute inflammatory
reaction in the bronchi. On day 7, the mucosal lesions had resolved, but on day
35, varying degrees of bronchitis and early bronchopneumonia with areas of
bulbous emphysema were seen. Gross pathology revealed varying degrees of
congestion, haemorrhage, oedema, interstitial emphysema, and collapse of
the lungs at all time points. Pulmonary resistance was increased throughout the
study (46).
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Table 6. Reported LC50 values in animals exposed via inhalation.
Species Exposure duration               LC50               Reference
  mg/m3   ppm
White rat   5 min  18 693 26 704 (154)
Mouse 10 min    7 060 10 152 (165)
Wistar rat 10 min  31 612 40 300 (8)
White rat 15 min  12 160 17 372 (154)
White rat 30 min    7 035 10 050 (154)
ICR mouse 1 h    2 960   4 230 (93)
CF1mouse 1 h    3 386   4 837 (118)
CFE rat 1 h    5 137   7 338 (118)
White rat 1 h    7 939 11 342 (154)
Wistar rat 1 h  11 620 16 600 (8)
White rat 2 h    7 600 10 860 (4)
LC50: lethal concentration for 50% of the exposed animals at single exposure.
Anaesthetised, mechanically ventilated rabbits exposed to very high levels of
nebulised ammonia (2 ml of 23-27% ammonia solution; estimated by the study
authors as peak ammonia concentrations of 35 000-39 000 ppm) for 4 minutes
had a decrease in blood oxygen saturation and an increase in airway pressure (a
measure of changes in airway resistance) (167). Arterial oxygen tension decreased
from 23.3 ± 3.6 kPa (mean ± standard deviation) to 11.0 ± 3.6 kPa and peak
airway pressure increased from 13 ± 2 cm H2O (mean ± standard deviation) to
17 ± 2 cm H2O.
Cardiovascular changes have been observed in rabbits exposed to high concen-
trations of ammonia for 1 hour (159). Bradycardia was seen at 2 500 ppm, and
hypertension and cardiac arrhythmias leading to cardiovascular collapse followed
acute exposures to concentrations exceeding 5 000 ppm. Atrophy of pericardial fat
has been observed in mice exposed to 4 000 ppm ammonia for 60 minutes (93).
In the LC50 study reported in Table 7, male CFE rats and male CF1 mice were
exposed to different ammonia concentrations for 60 minutes. Immediate nasal
and eye irritation was followed by laboured breathing and gasping in all study
groups. In addition, mild changes in the liver were seen at necropsy (118).
Table 7. Dose-effect relationships for 1-hour inhalation exposure in experimental animals
(118).
Species Exposure level Effect
  mg/m3        ppm
CFE rat 6 888 9 840 Liver fatty infiltration in 1/10 survivors
5 137 7 338 1-hour LC50
4 347 6 210 No pathological lesions in 10/10 survivors
CF1 mouse 4 004 5 720 Mild congestion in the liver in 1/10 survivors
3 386 4 837 1-hour LC50
2 520 3 600 No pathological lesions in 10/10 survivors
LC50: lethal concentration for 50% of the exposed animals at single exposure.
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10.3 Effects of short-term exposure
Studies in animals have demonstrated both dose-effect and duration-effect
relationships in changes at the respiratory tract. Acute exposures to lower
ammonia concentrations (less than 1 000 ppm) from 1 hour to 1 week cause
airway irritation, whereas exposures to high concentrations (4 000 ppm) for
3 hours to 2 weeks result in severe damage to the upper and lower respiratory
tract and alveolar capillaries (35, 93, 126, 158, 160).
Histopathological changes of the respiratory tract were evaluated in rats
continuously exposed to a mean ammonia concentration of 200 ppm, range
150-250 ppm, for 12 days. Progressive loss of cilia from and stratification of the
tracheal epithelial lining was observed. By day 12 a mucilaginous exudate was
apparent in the trachea together with a slight increase in submucosal cellularity
(61).
In a 2-month inhalation study on white rats a lowest observed adverse effect
level (LOAEL) of 100 mg/m3 (143 ppm) was determined based on histological
changes in the lungs, including small areas of interstitial pneumonia with signs of
peribronchitis and perivasculitis. No changes were reported in other organs as
compared with the control group. A threshold level for toxic effects of 40 mg/m3
(57 ppm) was reported from this study (5, cited in 87).
When rats, rabbits, guinea pigs, dogs and monkeys were continuously exposed
to ammonia at a concentration of 40 mg/m3 (57 ppm) for 114 days, no signs of
toxicity were seen and gross and microscopic examination did not reveal lung
abnormalities (35). A NOAEL of 40 mg/m3 (57 ppm) can be concluded from this
study.
Coon et al exposed Sprague-Dawley rats continuously by inhalation to 127
mg/m3 (181 ppm) and 262 mg/m3 (374 ppm) for 90 days (48 and 49 animals per
group, respectively) and to 455 mg/m3 (650 ppm) for 65 days (51 animals) (35).
The 181 ppm ammonia exposure (NOAEL) did not induce changes in gross or
microscopic pathology, haematology, or liver histochemistry. The exposure at 374
ppm (LOAEL) was without specific effects, but mild nasal discharge was seen in
25% of 49 rats. All the 51 rats exposed at 650 ppm showed mild dyspnoea and
nasal irritation. There were 32 deaths by day 25, and 50 deaths by day 65 in the
650 ppm group. Myocardial fibrosis was seen in rats, guinea pigs, rabbits, dogs,
and monkeys after prolonged (90 days) continuous exposure to 470 mg/m3 (671
ppm) (35). The contribution of these lesions to the morbidity and mortality of
affected animals was not determined.
Broderson et al exposed Sherman and Fisher rats to ammonia from natural
sources, at an average concentration of 150 ppm for 75 days, and to purified
ammonia at 250 ppm for 35 days (23). Histological changes in the olfactory and
respiratory epithelia of the nasal cavity were similar in all the exposed rats,
showing increased thickness, pyknotic nuclei, and hyperplasia. The submucosa
was oedematous with marked dilation of small vessels.
A concentration of 500 ppm was selected in a study of effects of continuous
exposure to ammonia, after noting that general toxic effects (particularly on
21
growth rate) were not present at 250-300 ppm (158). Young male specific-
pathogen-free rats were age- and weight-matched with controls (27 animals per
group) and exposed for up to 8 weeks. Nasal irritation began on the 4th day. After
3 weeks, exposed rats showed nasal irritation and inflammation of the upper
respiratory tract, but no effects were observed on the bronchioles and alveoli. The
number of pulmonary alveolar macrophages was similar to that of controls. After
8 weeks, no inflammatory lesions were present.
Swiss mice exposed to 909 ppm ammonia 6 hours/day, 5 days/week for 4-14
days expressed histological lesions in the respiratory epithelium in the nasal
cavity. These lesions were not seen at 303 ppm. No lesions were observed in the
trachea or lungs at any exposure level (201).
The nasal mucosa was adversely affected in adult male mice exposed to vapours
of a 12% ammonia solution for 15 minutes/day, 6 days/week for 4, 5, 6, 7, or 8
weeks (60). Histological changes progressed from weeks 4 to 8 from crowding of
cells forming crypts and irregular arrangements to epithelial hyperplasia, patches
of squamous metaplasia, loss of cilia, and dysplasia of the nasal epithelium.
Carcinomas were seen in two animals (see chapter 10.5 for more details).
Animal studies have revealed that ammonia affects the immune system.
Exposure of mice to ammonia at a concentration of 500 ppm for one week
followed by exposure to Pasteurella multocida at the lethal dose for 50% of the
exposed animals (LD50) increased the mortality significantly (158). A significant
increase in the severity of respiratory signs characteristic of murine respiratory
mycoplasmosis was observed in rats exposed to ammonia at 25 ppm for 4-6
weeks following inoculation with Mycoplasma pulmonis intranasally (23). Guinea
pigs exposed to 90 ppm for 3 weeks developed a significant decrease in the cell-
mediated immune response when challenged with a derivative of tuberculin (175).
Twelve guinea pigs were exposed to an ammonia concentration of about 170
ppm, range 140-200 for 6 hours/day, 5 days a week, for up to 18 weeks. There
were no significant findings at autopsy of animals sacrificed after 6 or 12 weeks
of exposure. In animals sacrificed after 18 weeks of exposure, there was conges-
tion of the liver, spleen, and kidneys, with early degenerative changes in the
adrenal glands. Increased erythrocyte destruction was explained by increased
quantities of haemosiderin in the spleen. In the proximal tubules of the kidneys,
there was cloudy swelling of the epithelium and precipitated albumin in the lumen
with some gasts. The cells of the adrenal glands were swollen and the cytoplasm
in some areas had lost its normal granular structure (193).
10.4 Mutagenicity and genotoxicity
No studies on mutagenicity and carcinogenicity of ammonia performed according
to current standards are available. Mutagenicity tests of ammonia have been
performed in Escherichia coli, chick fibroblast cells, and Drosophila melano-
gaster. Positive results were noted in a reverse mutation test in Escherichia coli,
but only in treatments using toxic levels of NH4+ (98% lethality) (43). Slight
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mutagenic activity was seen also in Drosophila following exposure to ammonia
gas, but survival after treatment was less than 2% (114).
Reduced cell division was noted in mouse fibroblasts cultured in media to
which ammonia and ammonia chloride were added (188). The effects were pH
independent. Decreased rate of DNA synthesis in vivo was observed in mouse
mucosal cells in the ileum and colon when serum NH4+ levels were significantly
elevated over normal levels. These elevated levels were induced by intraperitoneal
injection of urease or infusion of ammonium chloride (200).
10.5 Effects of long-term exposure and carcinogenicity
Oral exposure to 193 mg ammonium/kg body weight/day as ammonium hydroxide
in drinking water for two years did not produce carcinogenic effects in Swiss and
C3H mice, and had no effect on spontaneous development of breast adenocarci-
noma in C3H females, a characteristic of this strain (177).
No evidence of carcinogenic effects was found in CFLP mice treated intragastri-
cally with ammonia dissolved in water alone at a dose of 42 mg ammonium/kg/day
for 4 weeks or with diethyl pyrocarbonate (DEPC) alone, but 9/16 mice treated
with a combination of ammonium and DEPC developed lung tumours. The
ammonia and DEPC may have reacted in vivo to form the carcinogen, urethane,
which produced lung tumours in 9/9 of the mice (182). No lung tumours were
observed in the offspring of mice exposed similarly to ammonium and DEPC
during pregnancy or during lactation (183).
In a concomitant animal study, adult albino male mice (10 exposed, 5 controls)
were exposed to vapours of a 12% ammonia solution 15 minutes/day, 6 days/week
for 4, 5, 6, 7, or 8 weeks (60). All animals had histological changes in the
respiratory tract. In animals sacrificed after four and five weeks, the respiratory
epithelium revealed crowding of the cells forming crypts and irregular arrange-
ments. At week six, epithelial hyperplasia was noticed and in four animals of
ten exposed, patches of squamous metaplasia were seen. At week seven, three
exposed animals showed dysplasia in the nasal epithelium, while a carcinoma
in situ was detected in one nostril of one animal with loss of polarity of the
epithelium, hyperchromatism, and mitotic figures with an intact basement
membrane. At week eight, one mouse had an invasive adenocarcinoma of the
nasal mucosa. The levels and cell locations of succinic dehydrogenase, acid
phosphatase, alkaline phosphatase, and non-specific esterase activities were
altered, indicating altered cell metabolism and energy production, cell injury,
proliferation and possibly chronic inflammation and neoplastic transformation
(60).
Two studies indicate that the ammonium ion may act as a promoter of gastric
cancer in rats pretreated with the initiator N-methyl-N’-nitro-N-nitrosoguanidine
(MNNG) (178, 179). Male Sprague-Dawley rats administered 83 mg/l MNNG
in the drinking water for 24 weeks before receiving 0.01% ammonium in the
drinking water for 24 weeks had a statistically significantly greater incidence of
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gastric cancer (70% of rats) and number of tumours per tumour-bearing rat (2.1)
than rats receiving only MNNG and tap water (31% and 1.3 tumours/rat) (178).
Additionally, the size, depth, and metastasis of the MNNG-initiated tumours were
enhanced by ammonium (179).
These studies suggest that ammonium in the presence of certain other chemicals
(i.e. DEPC and MNNG) may contribute to the development of cancer (179, 182).
10.6 Reproductive and developmental studies
No data have been found regarding reproductive and developmental effects in
animals after inhalation exposure to ammonia.
In a study by Miñana et al, Wistar rats were exposed to ammonia from day 1
of gestation and through the prenatal and lactation periods via a diet containing
ammonium acetate (20% by mass) (133). After weaning (at postnatal day 21),
the pups were fed a normal diet with no ammonia added. The body weight of
offspring exposed to ammonia was significantly lower than that of controls, a
difference that was still evident one month after cessation of the exposure.
Primary cell cultures of cerebellar neurons from 8-day old offspring exhibited
impairment of the NMDA receptor function, as shown by decreased binding of
[3H]MK-801, increased resistance to glutamate and NMDA toxicity, and a lack
of increase in aspartate aminotransferase activity when small amounts of NMDA
were added to culture media (133). A study of similar design by Azorin et al, but
with adult male rats, observed significantly lower body weight of the male rats
maintained on the ammonium diet compared to the controls. Pair feeding showed
that this was due to a combination of lower food intake and lower caloric content
of the ammonium-enriched feed (13). Maternal body weight was not monitored
in the Miñana study, but the results from Azorin and co-workers make it very
probable, that maternal body weight was reduced during gestation.
Aguilar et al investigated the effect of perinatal hyperammonaemia on active
and passive avoidance behaviour and conditional discrimination learning in
male Wistar rats (2). Pre- and neonatal exposure to ammonia was carried out as
described above for Miñana et al (133). However, the exposure to ammonia was
continued also after weaning, until and during behavioural testing. Animals
exposed to ammonia already during prenatal life exhibited a decreased number
of active avoidances on one of five days of testing, and a decreased step-through
latency during passive avoidance. These effects were not observed in animals only
exposed to ammonia during postnatal life, indicating a prenatal component of
ammonia related effects. However, it should be noted that exposure to ammonia
during postnatal life was initiated only two weeks before behavioural testing. In
comparison, exposure of prenatally exposed animals was continued throughout
lactation and some additional weeks until behavioural testing (2).
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11. Observations in man
11.1 Irritation and sensitisation
Ammonia irritates the upper airways, eyes, and skin in humans. According to
two controlled human exposure studies clear signs of mild respiratory and eye
irritation appear somewhere between 25 and 50 ppm (80, 173) (see chapter 11.2
for more details).
Four out of six human subjects described moderate irritation of the nose and
eyes when exposed to 50 ppm, but not 30 ppm ammonia gas for 10 minutes (117).
When human volunteers were exposed to 100 ppm ammonia in each nostril of the
nasal airways for 30 seconds, a significant increase in airway resistance during the
exposure period was registered, and 11 out of 23 complained of nasal irritation
(128). In another study, human volunteers were exposed to various concentrations
of ammonia vapours for 5 minutes. At the concentration of 134 ppm, severe nose
irritation occurred in most subjects. At 72 ppm, several subjects reported the same
symptoms; at 50 ppm, two subjects reported nasal dryness; and at 32 ppm, one
subject reported nasal dryness (97, industrial report).
Ammonia has a greater tendency than other alkalis to penetrate and damage
the iris, and to cause cataract in severe burns. Iritis may be accompanied by hypo-
pyon (a layering of white blood cells in the anterior chamber) or haemorrhages,
extensive loss of pigment, and severe glaucoma (69, 76, 78). Two cases of ocular
injuries, with a rise in intraocular pressure and cataract formation after ammonia
(at unknown concentration) had been squirted into the victims’ eyes during rob-
beries, were reported (78). In both cases, the more severely affected eyes showed
marked injection and oedema of the conjunctivae, diffuse corneal damage, semi-
dilated, oval, and fixed pupils. A marked persistent increase in the intra-ocular
pressure was seen. An open angle glaucoma and cataract formation were seen in
both cases. One drop of a 9% ammonium hydroxide accidentally applied in a
patient’s eye resulted in an almost complete loss of the corneal epithelium despite
irrigation with water initiated within 10 seconds. The eye recovered completely
in 3-4 days (70).
Case reports on skin damage following accidental exposure to ammonia are
numerous but quantitative data are lacking. Most reports attribute described
injuries to the strong alkali effects of ammonia causing chemical burns (7, 196).
Direct contact with liquid anhydrous ammonia may cause frostbite in addition
to the burns. Anhydrous ammonia in concentrations of 10 000 ppm is sufficient
to evoke skin damage (7, 18). However, such high exposure levels are almost
certainly fatal if respiratory equipment is not used.
No data on human sensitisation from exposure to ammonia have been located
in the current literature.
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11.2 Effects of single and short-term exposure
There are several reports in the literature of acute human accidental inhalation
exposures to ammonia (26, 34, 63, 131, 194, 199). A review of the early literature
on ammonia toxicity cites acute exposure to 5 000-10 000 ppm as being rapidly
fatal in humans (134) and exposure to 2 500-4 500 ppm as being fatal in about
30 minutes (76, 132). Elevated levels of metabolites of hydroxylysine have been
observed in urine from ammonia accident victims. This indicates collagen
degradation secondary to inhalation injury (7).
Immediate deaths resulting from acute exposure to ammonia seems to be caused
by airway obstruction while infections and other secondary complications are lethal
factors among those who survive for several days or weeks. Chemical burns and
oedema of exposed tissues, including the respiratory tract, eyes, and exposed skin
are often observed after exposure to lethal levels (12). However, reliable measure-
ments of concentrations and durations of exposure are generally lacking (131).
In a liquefied ammonia production plant of the petrochemical industry, a 47-
year-old technician was exposed to ammonia for over 45 minutes after burst of a
pipe carrying liquefied ammonia. The patient manifested cutaneous, respiratory,
and ocular damage in addition to a severe cold thermal injury (frostbite), had
flaccid quadriparesis, and episodes of bradycardia (63). The accident had a fatal
outcome. The authors estimated the ammonia concentration to be between 2 000
and 2 500 ppm.
There is one case report on a 48-year old male who inhaled ammonia fumes as
a result of a train spill of urea. The patient developed symptomatology of burning
of the eyes and mouth, nausea, throat and mouth irritation. This complicated into
a state that was diagnosed as ammonia-induced sinusitis (20).
A lifelong non-smoker, and a victim of a massive accidental exposure to
anhydrous ammonia gas was followed for 10 years. In the acute phase, the patient
presented with severe tracheobronchitis and respiratory failure, caused by very
severe burns of the respiratory mucosa. After some improvement he was left with
severe and fixed airways obstruction. Isotope studies of mucociliary clearance,
computed tomography, and bronchography showed mild bronchiectasis. Thus,
acute exposure to high concentrations of ammonia leads to acute inhalation injury
but also to long-term impairment of respiratory function (42, 106).
Two painters, (one 41-year old and the other 45-year old with 20 and 25
years work experience, respectively), spray painted in a very poorly ventilated
apartment. The paint used was a one-stage vinyl latex primer containing 25%
ammonia and 16.6% aluminium chlorohydrate, and a number of other additives.
There were no isocyanates or anhydrides. After spray painting for 12 hours, the
two painters simultaneously noted the onset of generalised weakness, nausea,
cough, shortness of breath, paint taste in their mouths, chest tightness, and
wheezing. They were hospitalised for about two weeks with provisional diagnoses
of “acute chemical bronchitis”. After discharge from hospital, each subject
continued to note persistent wheezing, cough, exertional dyspnoea, and each
reported aggravation of symptoms after exposure to non-specific stimuli. At
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the University of Cincinnati the illness was designated as reactive airways dys-
function syndrome (RADS), an asthma-like syndrome with persistent bronchial
hyperreactivity but no sensitisation (24).
Six volunteers were exposed to 25, 50, and 100 ppm ammonia by inhalation
for 2-6 hours/day, 5 days/week for 6 weeks in an ammonium bicarbonate plant
(two subjects per exposure level). Suitable locations within the plant were selected
to achieve the desired ammonia concentrations. For the 100 ppm exposure level,
it was necessary to use a temporary exposure chamber and provide a source of
ammonia. Pulse rate, respiration rate, pulmonary functions (forced vital capacity
(FVC) and forced expiratory volume in one second (FEV1)), blood pressure,
neurological responses, and interferences in task-performance ability were
periodically examined. A statistical analysis of the results demonstrated that the
only significant change among the vital functions measured was an increase in
FEV1 with increasing ammonia concentration. Mild eye, nose, and throat irritation
was noted after examination by a physician, but an acclimatisation was suggested
by the authors as no discomfort was experienced by the subjects after the first
week. A clear dose-effect relationship was lacking. During occasional excursions
in the range of 150-200 ppm, all subjects experienced some watering of the eyes
and a sensation of dryness in the nose and throat (57). The results are difficult to
evaluate as the experimental design is unclear, the ammonia levels were not well
controlled and only two subjects per exposure level were used.
Sixteen volunteers (eight students with knowledge of the effects of ammonia
and eight students not familiar with ammonia health effects) were exposed four at
a time to 50, 80, 110 or 140 ppm ammonia for 2 hours. The respiratory variables
of vital capacity (VC), forced expiratory volume (FEV), and forced inspiratory
volume (FIV), measured before and after exposure, did not decrease by more
than 10%. During exposure, each participant recorded subjective effect levels for
smell, taste, irritation of eyes, nose, throat or breast, urge to cough, headache and
general discomfort every 15 minutes ranking them on a scale ranging from 0 to 5.
Subjective responses were ranked higher by those not familiar with the effects.
A concentration of 110 ppm was tolerated for 2 hours, but at 140 ppm, all the
subjects not familiar with the effects left the chamber because the exposure was
intolerable. The subjects experienced only mild irritation to eyes, nose, and throat
when exposed to 50 ppm (185).
Six healthy volunteers and eight subjects with mild asthma were exposed
to 16-25 ppm ammonia for 30 minutes. Neither healthy subjects nor asthmatics
showed any significant changes for pulmonary function (FEV1 and carbon
monoxide diffusing capacity) or bronchial hyperreactivity (metacholine chal-
lenge) (163).
Twelve healthy subjects (7 women, 5 men) were randomly exposed to sham or
ammonia (0, 5 and 25 ppm) for 3 hours in an exposure-chamber. The exposure to
ammonia did not significantly influence lung function, bronchial responsiveness
to metacholine, leucocyte counts and complement factors C3 and C3b in blood,
total cell count and interleukins 6 and 8 in nasal lavage, and exhaled nitric oxide
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levels. The authors reported that these ammonia exposures did not cause detec-
table upper-airway inflammation or increased bronchial responsiveness. However,
all symptom ratings (discomfort in the eyes, nose, throat and airways, breathing
difficulty, solvent smell, headache, fatigue, nausea, dizziness, and feeling
of intoxication) increased significantly during exposure to 25 ppm ammonia
compared to sham exposure. The symptoms remained constant during the
exposure, with no signs of adaptation. At 5 ppm, discomfort in the eyes, solvent
smell, headache, dizziness, and feeling of intoxication were significantly
increased. The average ratings of eye discomfort increased from “Not at all”
during sham exposure, to “Hardly at all” (approx. 6 mm on the 100-mm visual
analogue scale) at 5 ppm, and “Somewhat” (approx. 20 mm) at 25 ppm ammonia
(173). NEG therefore considers 5 ppm as a pragmatic NOAEL and 25 ppm as a
LOAEL for irritation.
In another study, 43 healthy males (whereof ten “habituated”, i.e. previously
exposed to ammonia at work) were exposed 4 hours daily to increasing levels
of ammonia on five consecutive days; day 1: 0 ppm, day 2: 10 ppm, day 3: 20
ppm, day 4: 20 ppm and two 30-minutes peaks of 40 ppm, and day 5: 50 ppm.
There was no significant trend over time for lacrimation, interleukins 6 and 8 in
nasal lavage, nasal resistance, lung function, and bronchial responsiveness to
acetylcholine. No effects on cognitive functions such as power of concentration,
attention, or reaction time were seen. The perceived intensity of symptoms and
annoyance (sum of symptom scores using the Swedish Performance Evaluation
System) increased significantly with increasing ammonia levels. The 33 non-
habituated tended to rate symptoms higher than the habituated subjects, although
this difference was not statistically significant. The rating of olfactory symptoms
was significantly increased already at the lowest level of ammonia (10 ppm)
among the non-habituated. Irritative and respiratory symptoms were significantly
increased in the non-habituated subjects but the exposure levels at which signifi-
cance was attained cannot be deduced from the report. At 50 ppm, eye irritation
(conjunctival hyperaemia) was seen in 3 of 33 non-habituated (9%). In habituated
subjects the irritative symptoms increased significantly only at 50 ppm whereas
the respiratory symptoms were not significantly increased at any level (80).
11.3 Effects of long-term exposure
Chronic occupational exposure (about 15 years) to low levels of ammonia
(9.2 ± 1.4 ppm) (mean ± standard error of mean) had no effect on respiratory or
cutaneous symptoms, pulmonary function, or odour sensitivity in 58 male workers
at a soda ash factory compared to 31 non-exposed controls (0.3 ± 0.1 ppm) from
the same factory (81).
Several studies have been conducted on farmers occupationally exposed to
ammonia in enclosed livestock buildings. In addition to ammonia total and
respirable dust, carbon dioxide, endotoxins, and microbes were measured (49, 50,
74, 75, 157). Of these pollutants ammonia (2.3-20.7 ppm) and dust (0.04-5.64
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mg/m3) were most frequently associated with respiratory effects, many of which
were temporary and disappeared with cessation of exposure. Reynolds et al used
regression equations for prediction of cross-shift change in pulmonary function
based on baseline pulmonary function and environmental exposure to dust,
endotoxin, and ammonia (157). The authors calculated the levels of dust (2.5
mg/m3) and ammonia (7.5 ppm) associated with a significant decrease in FEV1
over the work-shift among swine production workers. The previous dose-response
studies with swine workers resulted in exposure limit recommendations of 7 ppm
(47) and 7.5 ppm ammonia (50), based on a 3% decline in FEV1. The authors
emphasised that it was difficult to recommend any maximum concentrations for
exposure to ammonia, as correlations of ammonia to pulmonary function were
not as consistent as were the correlations of pulmonary functions to total dust
(50). Heederik et al examined 27 pig farmers and found a relationship between
ammonia exposure (5.6 mg/m3 ± 1.9) (geometric mean ± geometric standard
deviation) and decrease (5-10%) in lung function, although the change was
generally only of borderline significance (75). Donham et al studied a total of
257 poultry workers for respiratory symptoms, pulmonary function, and exposure
to dust, endotoxin, and ammonia (49). Significant dose-response relationships
studied by correlation and multiple regressions were observed between exposures
and pulmonary function decrements over a work shift. Exposure concentrations
associated with significant pulmonary function decrements were as follows:
total dust: 2.4 mg/m3, endotoxin: 614 endotoxin unit/m3 (61.4 ng/m3), and
ammonia 8.4 mg/m3 (12 ppm). In a later study on the same study population it
was calculated that synergy between ammonia levels and airborn dust explained
up to 43 and 63% of the decline (respectively for FEV1 and forced expiratory
flow rate between 25 to 75% of FVC) in pulmonary function over the work shift
(48). Vogelzang et al found a relationship between occupational exposure and
bronchial responsiveness in pig farmers and at re-examination three years later
the same authors demonstrated increased bronchial responsiveness, which was
associated with the exposure to ammonia and significantly associated with the
exposure to inhalable dust (189, 190). Most studies reported an association
between exposure to pollutants, including ammonia, in livestock confinement
buildings and an increase in respiratory symptoms (such as bronchial reactivity/
hyper-responsiveness, inflammation, cough, wheezing or shortness of breath)
and a decrease in pulmonary function. The data indicate that ammonia may
contribute to transient respiratory distress in exposed farmers but it cannot be
concluded to what extent, as the workers were also exposed to other respiratory
toxicants, namely dust and endotoxins (49, 50, 129).
A cross-sectional study investigated the prevalence of respiratory symptoms
(cough, phlegm, wheezing and dyspnoea) and diseases among 161 employees
chronically exposed to ammonia in two urea fertiliser producing factories and
355 unexposed controls (14). The 84 exposed subjects in the factory (A) with
ammonia levels ranging between 2 and 130 mg/m3 (3-182 ppm) had significantly
higher relative risks for all respiratory symptoms. The corresponding relative risks
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for the 77 subjects in the other factory (B) with considerably lower ammonia
levels (0.02-7 mg/m3 or 0.03-10 ppm) were non-significant. The geometric means
for ammonia were below 18 mg/m3 (25 ppm) except in the urea store and the
packing area of factory A with means of 115 and 18.6 mg/m3 (164 and 26.6 ppm),
respectively. Employees in the urea store were not allowed to enter the section
unless in full protective clothing. The prevalence rate of haemoptysis was also
significantly increased in factory A. All haemoptysis cases were reported to work
in areas with high ammonia exposures. Stratification by exposure level in the
total material showed significantly increased relative risks for cough (3.48, 95%
confidence interval (CI) 1.84-6.57), phlegm (3.75, 95% CI 1.97-7.11), wheezing
(5.01, 95% CI 2.38-10.57), dyspnoea (4.57, 95% CI 2.37-8.81) and bronchial
asthma (4.32, 95% CI 2.08-8.98) among subjects exposed to average ammonia
levels above 18 mg/m3 (25 ppm). Wheezing was also higher among those exposed
at or below 18 mg/m3 (2.26, 95% CI 1.32-3.88). Similarly, stratification by
cumulative ammonia levels showed significantly increased relative risks for all
four respiratory symptoms and asthma but also for chronic bronchitis in subjects
exposed above 50 mg/m3-years (70 ppm-years). Wheezing was significantly
higher in subjects exposed to cumulative ammonia levels at or below 50 mg/m3-
years (70 ppm-years). Logistic regression analysis revealed that the ammonia
concentration was significantly related to cough, phlegm, wheezing with and
without shortness of breath, and asthma. Furthermore, the ammonia concentration
was the only significant determinant for wheezing with shortness of breath and
asthma. The majority of the asthmatics worked in areas with high ammonia
concentrations (14). In a later study by the same authors, the effect of ammonia
exposure on pulmonary function (FEV1 and FVC) among 73 workers and 348
unexposed control subjects (most likely part of the study population described
above) was investigated (3). FEV1% predicted and FEV1/FVC% were lower and
FVC% predicted was significantly lower in controls than the workers. However,
the workers with high cumulative ammonia exposure (above 50 mg/m3-years)
had significantly lower FVC% predicted and FEV1% predicted than the workers
with lower cumulative exposure. Furthermore, the symptomatic workers (having
cough, phlegm, wheezing and/or dyspnoea) had significantly lower FEV1%
predicted and FEV1/FVC% than the workers without symptoms. After stratifica-
tion by smoking habit, the FEV1% predicted remained significantly lower among
the symptomatic non-smokers (3).
A 39-year old man with no past record of asthma developed symptoms of
cough, breathlessness, and wheezing after five months work with ammonia-
containing silver polish in a small poorly ventilated room (107). He could sense a
strong ammonia smell during polishing and the ammonia levels in breathing zone
were measured to be approximately 8-15 ppm. In addition to ammonia the silver
polish also contained isopropyl alcohol, clay, fatty acid, and water. The subject
had no symptoms during brass polishing with ammonia levels below 1 ppm. In a
controlled experiment, the subject developed rhinitis, tearing, and coughing about
15 minutes after starting polishing of silverware. Rhonchi were detected in both
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lungs and the peak expiratory flow rate (PEFR) fell by 42%. Nebulised ventolin
was given and PEFR was normalised but fell again 6 hours later. In another
experiment, the same patient was exposed to 12 ppm ammonia. Within 2 minutes
he had an asthmatic attack and rhonchi were detected in both lungs. Non-specific
bronchial hyperreactivity as assessed by histamine provocation was observed (107).
One case report describes a 68-year old male who was exposed to ammonia
and developed interstitial pulmonary fibrosis (21). The patient had been employed
for 18 years during which time he made photocopies and operated developing
equipment and cameras. He had been exposed frequently to anhydrous ammonia
leaks and described the odour of ammonia during these leaks. Throughout the
patient’s years of employment there were documented complaints about smell
of ammonia and symptoms during episodes of ammonia leaks at 30-400 ppm.
The ammonia concentrations in breathing zone samples taken during cylinder
change and where ammonia was sprayed ranged from 0-2 ppm and 15-20 ppm,
respectively (21).
The acute and chronic lung conditions that have been reported in association
with ammonia exposure are listed in Table 8. According to de la Hoz et al there
are few pathophysiologically well-characterised chronic pulmonary diseases due
to massive exposures to ammonia, and clinical follow-up for at least one year is
available for only a minority of the cases reported in the literature (42). This is in
part due to the acute mortality: death occurred instantaneously or in hospital
within 60 days of the exposure in 20 of the 94 reported cases examined by de la
Hoz et al (42). Death usually resulted from severe laryngeal oedema and obstruc-
tion, non-cardiogenic pulmonary oedema, or extensive pneumonic complications.
Inhalation injury has been infrequently associated with chronic interstitial lung
disease, with restrictive ventilatory pattern but case reports and indirect epidemio-
logical studies have described interstitial lung disease from ammonia exposure (21).
Table 8. Summary of pulmonary conditions associated with ammonia inhalation injury in
case reports. Adapted from de la Hoz et al (42).
Conditions   Reference
Acute
Pulmonary oedema (34, 44, 168)
Laryngitis/tracheobronchitis (with or without obstruction) (34, 106)
Bronchiolitis (168, 191)
Bronchopneumonia (44, 58, 168)
Reactive airways dysfunction syndrome (RADS) (24)
Chronic
Bronchiectasis (34, 94, 106)
Bronchospasm/asthma (17, 58)
Bronchiolitis (94, 168, 191)
Chronic obstructive pulmonary disease (COPD) (22, 111)
Interstitial pulmonary fibrosis (21)
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11.4 Genotoxic effects
Only one study was found in the current literature on the genotoxic effect of
ammonia on humans (198). Comparison of blood samples from 22 workers
exposed to ammonia in a fertiliser factory and 42 control workers not exposed to
ammonia showed increased frequency of chromosomal aberrations (CAs) and
sister chromatid exchanges (SCEs), increased mitotic index, and increased
frequency of CAs and SCEs with increasing length of exposure. The length of
workers’ exposure was 0-5 years (9 persons), 6-10 years (6 persons), and over 11
years (7 persons). In addition to ammonia, nitrogen fertiliser production involves
exposure to various nitrate compounds, which may have affected the results.
11.5 Carcinogenic effects
No data on carcinogenic effects of ammonia on humans were found in the
literature.
11.6 Reproductive and developmental effects
No data on reproductive and developmental effects of ammonia on humans were
found in the literature.
12. Dose-effect and dose-response relationships
12.1 Animal studies
Exposure to an ammonia concentration of 57 ppm for 60-114 days did not lead
to any sign of toxicity or lung abnormalities in any of the animal species tested
(5, 35). Histological changes in the lungs and respiratory tract appeared in rats
after 4-75 days exposure to 143-200 ppm ammonia (5, 23, 61). The RD50 value in
mice used as a measure of respiratory irritation in humans was calculated to be
257-303 ppm (15, 201). Dose-effect relationships after exposure to ammonia via
inhalation for experimental animals are listed in Table 9.
12.2 Human studies
According to two controlled human exposure studies (3-4 hours) clear signs of
mild respiratory and eye irritation appear somewhere between 25 and 50 ppm
(80, 173). No upper-airway inflammation or increased bronchial responsiveness
was seen at these levels. Chamber exposures to a concentration of 110 ppm was
tolerated for 2 hours, but at 140 ppm, all subjects not familiar with the effects left
the chamber because the exposure was intolerable (185).
Chronic occupational exposure to low levels of ammonia (9.2 ± 1.4 ppm)
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(mean ± standard error of mean) had no effect on respiratory or cutaneous symp-
toms, pulmonary function, or odour sensitivity (81). In another study, no signs of
respiratory symptoms were seen in workers exposed to ammonia concentrations
between 0.03 and 9.8 ppm. However, workers exposed to average ammonia levels
at or below 25 ppm had an increased relative risk for wheezing. Additionally, the
workers exposed to average levels above 25 ppm had higher relative risks for
wheezing, cough, phlegm, dyspnoea, and bronchial asthma (14). One case report
describes a man who developed asthma-like symptoms after five months exposure
to low levels of ammonia (8-15 ppm) from ammonia containing silver polish.
Subsequent experimental exposure to 12 ppm produced an immediate asthmatic
reaction (107). Dose-effect relationships after exposure to ammonia via inhalation
for humans are shown in Table 10.
13. Previous evaluations by national and international bodies
NEG concluded in 1986 that the significant effect of exposure to ammonia is
irritation of the respiratory tract, skin, and eyes. Studies of human inhalation of
ammonia at low or moderate concentrations (less than 50 mg/m3 = 70 ppm) had
shown mild eye and upper respiratory tract irritation. Exposure to high concentra-
tions of ammonia (by accidental release) may result in skin burns, eye damage,
respiratory injury, and death (110).
IPCS concluded that exposure to ammonia in air at a concentration of 390 ppm
(280 mg/m3) produced throat irritation; 1 680 ppm (1 200 mg/m3) produced
cough; 2 380 ppm (1 700 mg/m3) was life-threatening, and more than 4 900 ppm
(3 500 mg/m3) was associated with high mortality. Respiratory symptoms were
usually reversible, but chronic bronchitis had been reported to develop. Irritation
occurred at 50 ppm (35 mg/m3), which was neither discomforting nor painful.
However, the report further concluded that ammonia does not present a direct
threat to man except as a result of accidental exposure, particularly in industrial
settings (87).
The Health and Safety Executive (HSE), United Kingdom, summarised that the
only clearly established effect arising from exposure to low concentrations (less
than 200 ppm) of ammonia in humans is irritation of the skin, eyes, and upper
respiratory tract. In unaccustomed subjects, clear indications of irritation were
reported with exposure to 50-55 ppm for periods between several or 10 minutes
and 6 hours. There is some evidence that repeated exposure to ammonia may
lead to some degree of acclimatisation. The HSE report concluded that from the
very limited data available there is no clear evidence that ammonia possesses
genotoxic, carcinogenic, or reprotoxic potential (147).
Ammonia has not been classified for carcinogenic effects by United States
Environmental Protection Agency (EPA), United States Department of Health and
Human Services/National Toxicology Program (DHHS/NTP) or the International
Agency for Research on Cancer (IARC).
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In the criteria document for ammonia by the Commission of the European
Communities (1993) the current occupational exposure limit of 17 mg/m3 (25
ppm) was considered a borderline value. Therefore, an exposure limit of 14
mg/m3 (20 ppm) was suggested. If a short-term exposure limit (STEL) value will
be considered necessary, a level of 22 mg/m3 (32 ppm) was suggested (62).
The Agency for Toxic Substances and Disease Registry (ATSDR) has derived a
minimal risk level (MRL), of 1.7 ppm for acute-duration inhalation exposure, and
a MRL of 0.1 ppm for chronic-duration inhalation exposure to ammonia (12).
The American Conference of Governmental Industrial Hygienists (ACGIH) has
recommended an 8-hour occupational exposure limit of 25 ppm and a STEL of 35
ppm for ammonia. The first value is recommended to minimise the potential eye
and respiratory tract irritation and the second one to provide a greater margin of
safety against the acute sensory effects from exposure to ammonia (1).
14. Evaluation of human health risks
14.1 Assessment of health risks
Ammonia is an endogenous compound formed and used in various metabolic
reactions in the human body. The most serious effects of elevated endogenous
ammonia are seen in the brain as hepatic encephalopathy after acute or chronic
liver failure. At the cellular level, ammonia interacts with various cellular pro-
cesses involved in neurotransmission and brain energy metabolism.
The direct local action on mucous membranes results in irritation and
inflammation of the skin, eyes, nose, throat, and upper respiratory tract. Acute
contact with high concentrations of ammonia can produce rapid changes in the
pulmonary parenchyma due to the affinity of the anhydrous by-products for
mucous membranes leading to death. Clinically, mild insults produce coughing
as well as laryngitis and tracheobronchitis. Ammonia inhalation injury has also
been associated with RADS, an asthma-like syndrome with persistent bronchial
hyperreactivity but no sensitisation. More severe injuries include in fulminant
pulmonary oedema and bronchiectasis. The most frequent injury is desquamation
of the epithelial layer of the upper tracheobronchial tree.
Ammonia can penetrate and damage the iris, and cause cataract in severe
burns. Iritis may be accompanied by hypopyon (a layering of white blood cells in
the anterior chamber) or haemorrhages, extensive loss of pigment, and severe
glaucoma.
Chronic occupational exposure to low levels of ammonia (9.2 ± 1.4 ppm)
(mean ± standard error of mean) had no effect on pulmonary function or odour
sensitivity in a group of workers. In another study, chronic exposure to average
ammonia levels above 25 ppm was associated with increase in respiratory
symptoms and bronchial asthma.
According to two controlled human exposure studies clear signs of mild
respiratory and eye irritation appear somewhere between 25 and 50 ppm. In one
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of the studies, significant increases in symptom ratings were seen already at
5 ppm, however, the ratings corresponded verbally to “Hardly at all”. NEG
considers 5 ppm as a pragmatic NOAEL and 25 ppm as a LOAEL for irritation.
No upper-airway inflammation or increased bronchial responsiveness were
detected at these levels.
RD50 values for ammonia calculated from mouse studies are 260-300 ppm. A
NOAEL of 57 ppm and a LOAEL of 143 ppm for toxic effects were reported in a
2-month inhalation exposure of white rats. The NOAEL for irritation in humans is
often considered as approximately 3% of the RD50, i.e. 9 ppm ammonia.
14.2 Groups at extra risk
Ammonia is commonly regarded as an irritant. Therefore, persons who are hyper-
reactive to other respiratory irritants or who are asthmatic, would also be more
sensitive to ammonia. As ammonia is metabolised and excreted by liver and
kidney, persons with hepatic or renal impairment might be at risk when exposed
to ammonia as well as those with inherited deficiencies of urea cycle enzymes.
14.3 Scientific basis for an occupational exposure limit
Based on short-term (3-4 hours) controlled exposure of volunteers, the critical
effect of exposure to ammonia is irritation. According to these studies clear signs
of mild respiratory and eye irritation appear somewhere between 25 and 50 ppm.
In one of the studies, significant increases in symptom ratings were seen already
at 5 ppm, however, the ratings corresponded verbally to “Hardly at all”. NEG
considers 5 ppm as a pragmatic NOAEL and 25 ppm as a LOAEL for irritation.
No upper-airway inflammation or increased bronchial responsiveness were
detected at these levels. Chronic occupational exposure to low levels of ammonia
(9.2 ± 1.4 ppm) (mean ± standard error of mean) had no effect on pulmonary
function or odour sensitivity. In another study, chronic exposure to average
ammonia levels above 25 ppm was associated with an increase in respiratory
symptoms and bronchial asthma.
15. Research needs
Long-term animal tests are needed to establish a NOAEL for inhalation exposure.
There is a lack of data on health effects and exposure levels from long-term and
low exposure situations where ammonia is the principal agent. More studies on
health effects are also needed from persons who have been exposed to high levels
of ammonia. In addition, more studies on reproductive toxicity and carcinogeni-
city should be undertaken to provide proper data for risk assessment.
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16. Summary
Liesivuori J. The Nordic Expert Group for Criteria Documentation of Health
Risks from Chemicals. 137. Ammonia. Arbete och Hälsa 2005;13:1-52.
Ammonia (NH3) is a colourless gas with a distinctly pungent odour at normal
atmospheric temperatures and pressures. The odour threshold is approximately
5 ppm. Ammonia can be liquefied under pressure. In aqueous solution, NH3 acts
as a base yielding ammonium (NH4+) and hydroxide (OH-) ions. Because of the
high water solubility ammonia dissolves in moisture on the mucous membranes,
eyes and skin, forming ammonium hydroxide, which may cause alkali burns and
liquefaction necrosis of the tissues.
Ammonia occurs naturally in the environment and is endogenously produced in
humans and other mammalians. It is also man-made in vast quantities. Occupa-
tional exposures may occur in ammonia plants, fertiliser manufacturing, and
animal production. The primary route of occupational exposure to ammonia is
inhalation, although dermal exposure may also occur during handling of liquid
ammonia or aqueous ammonia solutions.
The critical effect of exposure to ammonia is irritation. In controlled human
exposure studies (3-4 hours) clear signs of mild respiratory and eye irritation
appear somewhere between 25 and 50 ppm. In one of these studies very slight
irritation was seen at 5 ppm. NEG considers 5 ppm as a pragmatic NOAEL and
25 ppm as a LOAEL for irritation. Chronic exposure to average ammonia levels
above 25 ppm has been associated with an increase in respiratory symptoms
(cough, wheezing, phlegm, and dyspnoea) and bronchial asthma. High acute
exposure levels may result in reactive airways dysfunction syndrome (RADS),
an asthma-like syndrome with persistent bronchial hyperreactivity but no
sensitisation. Massive exposure to ammonia can cause eye damage, skin burns,
severe inflammation of the respiratory tract (laryngitis, tracheobronchitis, and
pulmonary oedema), and death.
With very limited data available, there is no evidence that ammonia possesses
genotoxic, carcinogenic or reprotoxic potential.
Keywords: ammonia, asthma, burns, irritation, occupational exposure limit,
RADS, review, toxicity
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17. Summary in Swedish
Liesivuori J. The Nordic Expert Group for Criteria Documentation of Health
Risks from Chemicals. 137. Ammonia. Arbete och Hälsa 2005;13:1-52.
Ammoniak (NH3) är en färglös gas med en påtagligt stickande lukt vid normal
temperatur och tryck. Lukttröskeln har angivits till ungefär 5 ppm. Ammoniak
kondenserar till vätska vid högt tryck. Ammoniak är en svag bas som i vatten
bildar ammonium- (NH4+) och hydroxidjoner (OH-). Den höga vattenlösligheten
gör att ammoniak löser sig i slemhinnor, ögon och hud och bildar ammonium-
hydroxid som i sin tur kan orsaka frätskador och nekros.
Ammoniak förekommer naturligt i vår omgivning och bildas endogent hos
människor och andra däggdjur. Ammoniak framställs också industriellt i stora
kvantiteter. Förutom vid råvaru- och handelsgödselproduktion förekommer
ammoniakexponering framförallt inom jordbruket i samband med djurhållning.
Yrkesmässig exponering för ammoniak sker främst genom inhalation. Hudupptag
kan ske vid hantering av flytande ammoniak eller vattenlösningar av ammoniak.
Den kritiska effekten vid exponering för ammoniak är irritation. I kontrollerade
exponeringsstudier på människa (3-4 timmar) uppträder tydliga tecken på mild
irritation i övre luftvägar och i ögon någonstans mellan 25 och 50 ppm. I en av
dessa studier noterades en mycket svag irritation vid 5 ppm. NEG bedömer 5 ppm
som en pragmatisk icke-effektnivå (NOAEL) och 25 ppm som lägsta observerade
effektnivån (LOAEL) för irritation. Kronisk exponering för en genomsnittlig
ammoniaknivå över 25 ppm har rapporterats vara förenat med en ökning av
luftvägssymptom (hosta, pipande andning, slem och andnöd) och bronkiell astma.
Akut exponering för höga halter ammoniak kan ge upphov till ett astma-liknande
sjukdomstillstånd, s k RADS (reactive airways dysfunction syndrome) som
kännetecknas av kvarstående bronkiell hyperreaktivitet men ingen sensibilisering.
Massiv exponering för ammoniak kan orsaka frätskador på hud och ögon,
allvarlig inflammation i luftvägarna (laryngit, trakeobronkit och lungödem) och
leda till döden.
Det går inte att bedöma om ammoniak har genotoxisk, carcinogen eller
reproduktiontoxisk potential med tillgängliga data.
Nyckelord: ammoniak, astma, frätskador, irritation, hygieniskt gränsvärde, RADS,
toxicitet, översikt
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19. Data bases used in the search for literature
In the search for literature the following data bases were used:
Arbline
Chemical Abstracts
HSELINE
Medline
NIOSHTIC
Toxline
PubMed (National Library of Medicine)
Last search was performed in April 2005.
Submitted for publication October 27, 2005.
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Appendix
Occupational exposure limits for ammonia in air.
Country (Organisation)   ppm
  μg/m3 Comments Year Reference
Denmark 20 14 2005 (1)
Finland 20 14 2005 (2)
50 36 STEL, 15 min, 2005 (2)
Germany 20 14 2005 (3)
Iceland 25 18 1999 (4)
50 35 STEL, 5 min 1999 (4)
Netherlands 20 14 2005 (5)
50 36 STEL, 15 min 2005 (5)
Norway 25 18 2003 (6)
Sweden 25 18 2005 (7)
50 35 STEL, 5 min 2005 (7)
USA (ACGIH) 25 2005 (8)
35 STEL, 15 min 2005 (8)
(NIOSH) 25 18 2005 (9)
35 27 STEL, 15 min 2005 (9)
(OSHA) 50 35 2005 (9)
STEL: short-term exposure limits.
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